Business
Kalaris Expands Board of Directors Appointing Leone Patterson as Chair of Audit Committee
Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growthPALO ALTO, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Leone Patterson to its Board of Directors and as Chair of the Board’s Audit Committee. “We’re delighted t
About this update from Kalaris Therapeutics, Inc.
[{"type":"image","alt":"Kalaris Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Kalaris Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":140,"height":40,"url":"https://media.zenfs.com/en/globenewswire.com/fdbb7c94867cf52e75aaccd6c74b0d21"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/omsWelxSjfpb3wGCdv4fDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTYwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/fdbb7c94867cf52e75aaccd6c74b0d21","width":140,"height":40}},"lazy":false},{"type":"text","content":"Highly experienced biotech executive and board member will assist Kalaris in achieving its next phase of growth","length":111,"tagName":"p"},{"type":"text","content":"PALO ALTO, Calif., April 04, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Leone Patterson to its Board of Directors and as Chair of the Board’s Audit Committee.","length":370,"tagName":"p"},{"type":"text","content":"“We’re delighted to welcome Leone as Chair of the Board’s Audit Committee,” said David Hallal, Chairman of the Kalaris Board of Directors. “Leone is joining us at the pinnacle of her career as a senior financial executive in biotech with strong strategic and operational capabilities. Leone will be an outstanding addition to our Board of Directors. We look forward to her contributions and expertise as we continue to develop and grow Kalaris.”","length":445,"tagName":"p"},{"type":"text","content":"Leone Patterson said, “I am thrilled to join Kalaris Therapeutics’ Board of Directors. The company’s lead asset along with its experienced management team and Board, represent a significant opportunity to evolve the treatment paradigm in retinal diseases.”","length":256,"tagName":"p"},{"type":"text","content":"Ms. Patterson serves as Zymeworks’ Executive Vice President, Chief Business Officer and Chief Financial Officer where she is responsible for corporate finance and accounting, business development and other operational functions. Ms. Patterson previously served as Chief Financial and Business Officer at Tenaya Therapeutics where she led corporate finance, investor relations, corporate communications, strategy and busine...